Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · IEX Real-Time Price · USD
2.320
+0.020 (0.87%)
At close: May 23, 2024, 4:00 PM
2.280
-0.040 (-1.72%)
After-hours: May 23, 2024, 7:11 PM EDT

Oramed Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2006
Revenue
1.342.72.72.712.7
Upgrade
Revenue Growth (YoY)
-50.43%0%-0.26%0.26%10.37%
Upgrade
Cost of Revenue
00000.09
Upgrade
Gross Profit
1.342.72.72.712.61
Upgrade
Selling, General & Admin
8.1415.665.944.233.72
Upgrade
Research & Development
8.9727.6420.9910.2413.52
Upgrade
Operating Expenses
17.1143.326.9314.4717.24
Upgrade
Operating Income
-15.77-40.6-24.22-11.76-14.63
Upgrade
Interest Expense / Income
2.0400.010.440.49
Upgrade
Other Expense / Income
-23.33-4.14-1.99-0.69-1.06
Upgrade
Pretax Income
5.53-36.46-22.24-11.51-14.06
Upgrade
Income Tax
00.1000.3
Upgrade
Net Income
5.53-36.56-22.24-11.51-14.36
Upgrade
Shares Outstanding (Basic)
4039282117
Upgrade
Shares Outstanding (Diluted)
4139282117
Upgrade
Shares Change
4.02%36.98%38.65%17.63%17.28%
Upgrade
EPS (Basic)
0.14-0.94-0.78-0.56-0.82
Upgrade
EPS (Diluted)
0.14-0.94-0.78-0.56-0.82
Upgrade
Free Cash Flow
-10.55-28.39-21.56-12.52-12.96
Upgrade
Free Cash Flow Per Share
-0.26-0.73-0.76-0.61-0.74
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%96.67%
Upgrade
Operating Margin
-1176.79%-1501.96%-896.15%-433.84%-541.29%
Upgrade
Profit Margin
412.31%-1352.61%-822.72%-424.76%-531.08%
Upgrade
Free Cash Flow Margin
-787.24%-1050.31%-797.48%-462.07%-479.28%
Upgrade
EBITDA
7.76-36.4-22.15-11.06-13.56
Upgrade
EBITDA Margin
578.96%-1346.76%-819.57%-408.12%-501.74%
Upgrade
Depreciation & Amortization
0.20.060.080.010.01
Upgrade
EBIT
7.56-36.46-22.23-11.07-13.57
Upgrade
EBIT Margin
564.33%-1348.91%-822.42%-408.38%-502.03%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).